Detected ·
Watershed Therapeutics
——
Eli Lilly and Company has invested in Watershed Therapeutics to advance SHED-01, its gemcitabine program for non-muscle-invasive bladder cancer (NMIBC), toward a first-in-patient study.
- Website
- watershedtx.com
- linkedin.com/company/43283365
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-11-17 12:16:23 UTC
- Signal ID
- 0f8b9c5e-1874-4f9c-b2eb-0bbb55ce0ba9
As the API returns it
{
"id": "0f8b9c5e-1874-4f9c-b2eb-0bbb55ce0ba9",
"created_at": "2026-11-17T12:16:23.982454Z",
"company_name": "Watershed Therapeutics",
"company_website_url": "watershedtx.com",
"company_linkedin_url": "https://www.linkedin.com/company/43283365",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*Eli Lilly and Company has invested in Watershed Therapeutics to advance SHED-01, its gemcitabine program for non-muscle-invasive bladder cancer (NMIBC), toward a first-in-patient study.*"
}